Patents by Inventor Toshio Kanai
Toshio Kanai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230287009Abstract: Provided is a novel compound that has an excellent ?-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent ?-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a ?-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and ?-lactam drugs.Type: ApplicationFiled: April 28, 2023Publication date: September 14, 2023Applicants: Sumitomo Pharma Co., Ltd., THE KITASATO INSTITUTEInventors: Toshio KANAI, Sachiko KOIKE, Takayuki FUKAYA, Shunichiro UESUGI, Shingo MIZUSHIMA, Hitoshi SUDA, Yuki MIZUKAMI, Yohei IKUMA, Toshiaki SUNAZUKA, Yoshihiko NOGUCHI
-
Patent number: 11702431Abstract: Provided is a novel compound that has an excellent ?-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent ?-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a ?-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and ?-lactam drugs.Type: GrantFiled: April 26, 2019Date of Patent: July 18, 2023Assignees: Sumitomo Pharma Co., Ltd., THE KITASATO INSTITUTEInventors: Toshio Kanai, Sachiko Koike, Takayuki Fukaya, Shunichiro Uesugi, Shingo Mizushima, Hitoshi Suda, Yuki Mizukami, Yohei Ikuma, Toshiaki Sunazuka, Yoshihiko Noguchi
-
Patent number: 11066372Abstract: The present invention relates to a medicament for treating or preventing a disease involving Na channel, for example, neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, or multiple sclerosis, comprising a compound of formula (I) wherein R1a, R1b, R1c, and R1d are hydrogen, halogen, cyano, C1-4 alkyl, C1-4 alkoxy, etc., provided that at least one of R1a, R1b, R1c and R1d is the above C6-10 aryl, C6-10 aryloxy, etc., R2 and R3 are hydrogen, C1-6 alkyl, C3-10 cycloalkyl, etc., R4 is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, etc., m is 0, 1, or 2, L is CR7R8, R7 and R8 are hydrogen, hydroxy group, C1-4 alkyl, C1-4 alkoxy, etc., or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 14, 2018Date of Patent: July 20, 2021Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Toshio Kanai, Kohei Iwamoto
-
Patent number: 11066425Abstract: Provided is a novel compound that has an excellent ?-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent ?-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a ?-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and ?-lactam drugs.Type: GrantFiled: December 29, 2020Date of Patent: July 20, 2021Assignees: SUMITOMO DAINIPPON PHARMA CO., LTD., THE KITASATO INSTITUTEInventors: Toshio Kanai, Sachiko Koike, Takayuki Fukaya, Shunichiro Uesugi, Shingo Mizushima, Hitoshi Suda, Yuki Mizukami, Yohei Ikuma, Toshiaki Sunazuka, Yoshihiko Noguchi
-
Publication number: 20210147448Abstract: Provided is a novel compound that has an excellent ?-lactamase inhibitory effect. More specifically, provided is a compound represented by formula (1a), (1b) or (11) having an excellent ?-lactamase inhibitory effect or a pharmaceutically acceptable salt thereof. By using this compound either in combination with a ?-lactam drug or alone, a useful preventive or therapeutic agent for bacterial infections is provided. Also provided are useful preventive or therapeutic agents for treating various diseases with the combined use of the aforesaid compound and ?-lactam drugs.Type: ApplicationFiled: April 26, 2019Publication date: May 20, 2021Applicants: SUMITOMO DAINIPPON PHARMA CO., LTD., THE KITASATO INSTITUTEInventors: Toshio KANAI, Sachiko KOIKE, Takayuki FUKAYA, Shunichiro UESUGI, Shingo MIZUSHIMA, Hitoshi SUDA, Yuki MIZUKAMI, Yohei IKUMA, Toshiaki SUNAZUKA, Yoshihiko NOGUCHI
-
Publication number: 20200017450Abstract: The present invention relates to a medicament for treating or preventing a disease involving Na channel, for example, neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, or multiple sclerosis, comprising a compound of formula (I) wherein R1a, R1b, R1c, and R1d are hydrogen, halogen, cyano, C1-4 alkyl, C1-4 alkoxy, etc., provided that at least one of R1a, R1b, R1c and R1d is the above C6-10 aryl, C6-10 aryloxy, etc., R2 and R3 are hydrogen, C1-6 alkyl, C3-10 cycloalkyl, etc., R4 is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, etc., m is 0, 1, or 2, L is CR7R8, R7 and R8 are hydrogen, hydroxy group, C1-4 alkyl, C1-4 alkoxy, etc., or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 14, 2018Publication date: January 16, 2020Inventors: Toshio Kanai, Kohei Iwamoto
-
Patent number: 10407395Abstract: The present invention provides a medicament for treating a disease involving Nav 1.7 such as neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, and multiple sclerosis, which comprises a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c and R1d are hydrogen, halogen, cyano, C1-4 alkyl, C1-4 alkoxy, or the like, provided that at least one of R1a, R1b, R1c and R1d is C6-10 aryl, C6-10 aryloxy, or the like, R2 and R3 are hydrogen, C1-6 alkyl, C3-10 cycloalkyl, or the like, R4 is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, or the like, m is 1, 2 or 3, L is CR7R8, and R7 and R8 are hydrogen, hydroxyl, C1-4 alkyl, C1-4 alkoxy, or the like.Type: GrantFiled: September 9, 2016Date of Patent: September 10, 2019Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Masafumi Komiya, Kohei Iwamoto, Toshio Kanai, Shingo Mizushima, Keiji Adachi, Kuniko Urashima
-
Publication number: 20190241569Abstract: The invention provides novel inhibitors of cancer stem cells as well as cancer stem cell pathway kinase and other related kinases, pharmaceutical compositions and uses thereof in the treatment of cancer or a related disorder in a mammal, and methods of making such compounds and compositions.Type: ApplicationFiled: November 30, 2018Publication date: August 8, 2019Inventors: Chiang Jia Li, Ji-Feng Liu, Wei Li, Amanda Gibeau, Harry Rogoff, Katsunori Tsuboi, Yosuke Takanashi, Shingo Tojo, Tomohiro Kodama, Katsumi Kubota, Toshio Kanai
-
Publication number: 20190241550Abstract: Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, R1 is optionally substituted heteroaryl etc.; R2 is hydrogen etc.; R3 and R4 are each independently hydrogen etc., R5 is the following group: (wherein Y is optionally substituted five membered heteroaryl etc., R9a is optionally substituted aryl etc., R9b and R9c are each dependently hydrogen etc., and m is the integral 0 etc.) etc.; R6 is hydrogen etc.; and R7 is hydrogen etc.Type: ApplicationFiled: October 11, 2018Publication date: August 8, 2019Inventors: Katsunori Tsuboi, Yosuke Takanashi, Shingo Tojo, Tomohiro Kodama, Katsumi Kubota, Toshio Kanai
-
Publication number: 20180170881Abstract: The present invention provides a medicament for treating a disease involving Nav 1.7 such as neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, and multiple sclerosis, which comprises a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c and R1d are hydrogen, halogen, cyano, C1-4 alkyl, C1-4 alkoxy, or the like, provided that at least one of R1a, R1b, R1c and R1d is C6-10 aryl, C6-10 aryloxy, or the like, R2 and R3 are hydrogen, C1-6 alkyl, C3-10 cycloalkyl, or the like, R4 is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, or the like, m is 1, 2 or 3, L is CR7R8, and R7 and R8 are hydrogen, hydroxyl, C1-4 alkyl, C1-4 alkoxy, or the like.Type: ApplicationFiled: September 9, 2016Publication date: June 21, 2018Inventors: Masafumi Komiya, Kohei Iwamoto, Toshio Kanai, Shingo Mizushima, Keiji Adachi, Kuniko Urashima
-
Patent number: 9688670Abstract: The present invention provides a medicament for treating a disease involving Nav 1.7 such as neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, and multiple sclerosis, which comprises a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c and R1d are hydrogen, halogen, cyano, C1-4 alkyl, C1-4 alkoxy, or the like, provided that at least one of R1a, R1b, R1c and R1d is C6-10 aryl, C6-10 aryloxy, or the like, R2 and R3 are hydrogen, C1-6 alkyl, C3-10 cycloalkyl, or the like, R4 is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, or the like, m is 1, 2 or 3, L is CR7R8, and R7 and R8 are hydrogen, hydroxyl, C1-4 alkyl, C1-4 alkoxy, or the like.Type: GrantFiled: December 30, 2016Date of Patent: June 27, 2017Assignee: Sumitomo Dainippon Pharma Co., Ltd.Inventors: Masafumi Komiya, Kohei Iwamoto, Toshio Kanai, Shingo Mizushima, Keiji Adachi, Kuniko Urashima
-
Publication number: 20170107211Abstract: The present invention provides a medicament for treating a disease involving Nav 1.7 such as neuropathic pain, nociceptive pain, inflammatory pain, small-fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, dysuria, and multiple sclerosis, which comprises a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1a, R1b, R1c and R1d are hydrogen, halogen, cyano, C1-4 alkyl, C1-4 alkoxy, or the like, provided that at least one of R1a, R1b, R1c and R1d is C6-10 aryl, C6-10 aryloxy, or the like, R2 and R3 are hydrogen, C1-6 alkyl, C3-10 cycloalkyl, or the like, R4 is hydrogen, C1-6 alkyl, C3-7 cycloalkyl, or the like, m is 1, 2 or 3, L is CR7R8, and R7 and R8 are hydrogen, hydroxyl, C1-4 alkyl, C1-4 alkoxy, or the like.Type: ApplicationFiled: December 30, 2016Publication date: April 20, 2017Inventors: Masafumi Komiya, Kohei Iwamoto, Toshio Kanai, Shingo Mizushima, Keiji Adachi, Kuniko Urashima
-
Publication number: 20160221948Abstract: The present invention provides a compound represented by the following formula (I) or its pharmaceutically acceptable salt: [wherein, R1 represents optionally substituted C1-4 alkyl, n shows integer of 1 to 4, R2 represents optionally substituted C1-4 alkyl or hydrogen atom, R3 represents optionally substituted C1-4 alkyl, R4a, R4b, R4c, and R4d, similarly or differently, represent optionally substituted C6-14 aryl, optionally substituted C1-4 alkyl, or hydrogen atom and the like, A represents optionally substituted C6-14 aryl or optionally substituted 5 to 11 membered heteroaryl].Type: ApplicationFiled: September 12, 2014Publication date: August 4, 2016Inventors: Akira FUSANO, Tomonori KOBAYASHI, Yasuhiro SAITO, Toshio KANAI
-
Publication number: 20160075697Abstract: Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, R1 is optionally substituted heteroaryl etc.; R2 is hydrogen etc.; R3 and R4 are each independently hydrogen etc., R5 is the following group: (wherein Y is optionally substituted five membered heteroaryl etc., R9a is optionally substituted aryl etc., R9b and R9c are each dependently hydrogen etc., and m is the integral 0 etc.) etc.; R6 is hydrogen etc.; and R7 is hydrogen etc.Type: ApplicationFiled: November 24, 2015Publication date: March 17, 2016Inventors: Katsunori Tsuboi, Yosuke Takanashi, Shingo Tojo, Tomohiro Kodama, Katsumi Kubota, Toshio Kanai
-
Publication number: 20160031888Abstract: The invention provides compounds of Formula I as inhibitors of cancer stem cells as well as cancer stem cell pathway kinase and other related kinases, pharmaceutical compositions and uses thereof in the treatment of cancer or a related disorder in a mammal, wherein i.a. R2 is an optionally substituted heterocycle or optionally substituted aryl; and one of R4, R5, R6 and R7 is a substituted heterocycle or substituted aryl.Type: ApplicationFiled: March 13, 2014Publication date: February 4, 2016Applicant: BOSTON BIOMEDICAL, INC.Inventors: Chiang Jia Li, Ji-feng Liu, Wei Li, Amanda Gibeau, Harry Rogoff, Katsunori Tsuboi, Yosuke Takanashi, Shingo Tojo, Tomohiro Kodama, Katsumi Kubota, Toshio Kanai
-
Patent number: 9227962Abstract: Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, R1 is optionally substituted heteroaryl etc.; R2 is hydrogen etc.; R3 and R4 are each independently hydrogen etc., R5 is the following group: (wherein Y is optionally substituted five membered heteroaryl etc., R9a is optionally substituted aryl etc., R9b and R9c are each dependently hydrogen etc., and m is the integral 0 etc.) etc.; R6 is hydrogen etc.; and R7 is hydrogen etc.Type: GrantFiled: March 13, 2014Date of Patent: January 5, 2016Assignee: Boston Biomedical, Inc.Inventors: Katsunori Tsuboi, Yosuke Takanashi, Shingo Tojo, Tomohiro Kodama, Katsumi Kubota, Toshio Kanai
-
Publication number: 20140275076Abstract: Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, R1 is optionally substituted heteroaryl etc.; R2 is hydrogen etc.; R3 and R4 are each independently hydrogen etc., R5 is the following group: (wherein Y is optionally substituted five membered heteroaryl etc., R9a is optionally substituted aryl etc., R9b and R9c are each dependently hydrogen etc., and m is the integral 0 etc.) etc.; R6 is hydrogen etc.; and R7 is hydrogen etc.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Inventors: Katsunori Tsuboi, Yosuke Takanashi, Shingo Tojo, Tomohiro Kodama, Katsumi Kubota, Toshio Kanai
-
Publication number: 20110263550Abstract: Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below: or a pharmaceutically acceptable salt of the compound or a prodrug of the compound or salt: wherein X represents an oxygen or sulfur atom; R1 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; Y1 represents single bond, a substituted or unsubstituted alkylene or the like; the wavy line means an (E) or (Z) coordination; R3 represents a hydrogen atom, a substituted or unsubstituted aryl or the like; Y2 represents a substituted or unsubstituted alkylene or an alkenylene; R4 represents a hydrogen atom, a substituted or unsubstituted alkanoyl or the like; and R5 represents a hydrogen atom or a substituted or unsubstituted alkyl.Type: ApplicationFiled: April 11, 2011Publication date: October 27, 2011Applicant: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshinari Sugasawa, Takashi Nakajima, Hitoshi Fujita, Toshio Kanai
-
Patent number: 8012971Abstract: Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below: or a pharmaceutically acceptable salt of the compound or a prodrug of the compound or salt: wherein X represents an oxygen or sulfur atom; R1 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; R2 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; Y1 represents single bond, a substituted or unsubstituted alkylene or the like; the wavy line means an (E) or (Z) coordination; R3 represents a hydrogen atom, a substituted or unsubstituted aryl or the like; Y2 represents a substituted or unsubstituted alkylene or an alkenylene; R4 represents a hydrogen atom, a substituted or unsubstituted alkanoyl or the like; and R5 represents a hydrogen atom or a substituted or unsubstituted alkyl.Type: GrantFiled: April 28, 2006Date of Patent: September 6, 2011Assignee: Dainippon Sumitomo Pharma Co., Ltd.Inventors: Toshinari Sugasawa, Takashi Nakajima, Hitoshi Fujita, Toshio Kanai
-
Publication number: 20110034466Abstract: Disclosed is a five-membered ring compound represented by formula (1) or a pharmaceutically acceptable salt thereof. The compound inhibits infiltration of leukocytes including eosinophils and lymphocytes, and is effective as a drug for treating various inflammations. The compound is highly safe and can be administered for a long period. A pharmaceutical product containing the five-membered ring compound or a pharmaceutically acceptable salt thereof is also disclosed.Type: ApplicationFiled: April 23, 2009Publication date: February 10, 2011Inventors: Hitoshi Fujita, Toshio Kanai, Satoki Imai